FDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
The FDA approved Sunharbo (asundexian) 50 mg tablets alongside antiplatelet therapy for adults who recently had a mild-to-moderate noncardioembolic ischemic stroke or a high-risk TIA. It's the first factor XIa inhibitor greenlit for use with antiplatelets, backed by a 12,327-patient phase 3 trial that cut ischemic stroke risk by 26%.
- Original source: medicalxpress.com.
- The source published it on Nov 17, 2026 at 6:21 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA has approved Sunharbo (asundexian) 50 mg tablets, taken with antiplatelet therapy, to lower stroke risk in adults who recently suffered a mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack. It becomes the first factor XIa inhibitor cleared for use alongside antiplatelet therapy.
The green light rests on OCEANIC-STROKE, a phase 3 study that randomized 12,327 adults within 72 hours of symptom onset. Participants had a noncardioembolic ischemic stroke scoring 15 or lower on the NIH Stroke Scale, or a high-risk TIA, and all received antiplatelet therapy on top of either Sunharbo or placebo. Sunharbo 50 mg once daily cut the risk of ischemic stroke by 26% compared with placebo across a median treatment period of 14.2 months.
Bleeding looked broadly comparable between the two arms, though major bleeding ticked up with Sunharbo in patients older than 75 and during the first 90 days of treatment. Diarrhea was the most commonly reported adverse reaction, hitting at least 3% of Sunharbo-treated patients, and gastrointestinal bleeding showed up more often than with placebo.
The label carries several limits. Combining Sunharbo with medicines that are both P-gp and strong CYP3A4 inducers isn't recommended because it weakens the drug's effectiveness, and it isn't advised for patients with moderate or severe hepatic impairment. The FDA also did not approve it for stroke prevention in people with atrial fibrillation.
Ashkan Shoamanesh, M.D., co-principal investigator of OCEANIC-STROKE at McMaster University, framed the timing in a statement: the danger of a repeat event is steepest in the days and weeks right after a first stroke, and it never fully fades. He called Sunharbo an important new addition to poststroke care that can help patients reduce the risk of a secondary stroke.
TopicsFDA · Sunharbo · asundexian · OCEANIC-STROKE · Ashkan Shoamanesh · McMaster University
Source: medicalxpress.com
Written by AI from verified reporting. Not financial advice.
More stories
- Health & science medicalxpress.com 0 viewsFDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
- Health & science france24.com 1 viewWHO warns drug resistance is outpacing the world's response
- Health & science aol.com 2 viewsFDA Approves Beren's LEMBAZ, First Drug to Improve Survival in Infantile NPC
- Health & science fiercepharma.com 1 viewGSK's Nelkarmi wins FDA nod for ALK lung cancer, capping a three-approval run

